Axsome Therapeutics. has been granted a patent for a method to reduce adverse events, including insomnia, in infants fed breast milk from mothers treated with solriamfetol. The method involves administering solriamfetol to the mother and timing breastfeeding to minimize infant exposure. GlobalData’s report on Axsome Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Axsome Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Axsome Therapeutics's grant share as of July 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Method to reduce insomnia risk in breastfed infants
A recently granted patent (US12064411B1) outlines a method aimed at reducing the risk of insomnia in infants who are breastfed by mothers treated with solriamfetol, a medication commonly used to address excessive daytime sleepiness. The method involves administering solriamfetol to the mother at a daily dose of approximately 150 mg or 75 mg, depending on the claim, while ensuring that the infant receives a daily dose of solriamfetol of about 0.3 mg or 0.15 mg, respectively. Crucially, the infant is fed breast milk at least five hours after the mother has taken the medication, which is intended to minimize the potential for insomnia in the infant.
The patent specifies that the method is applicable to mothers who are within 1 day to 24 months postpartum, with a particular focus on those aged between 18 and 50 years. It also encompasses various conditions for which the mother may be receiving solriamfetol treatment, including narcolepsy, obstructive sleep apnea, attention deficit hyperactivity disorder, and cognitive impairments. The claims further assert that the method can effectively prevent insomnia in the infant, thereby providing a framework for safe breastfeeding practices for mothers undergoing treatment with solriamfetol.
To know more about GlobalData’s detailed insights on Axsome Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
